Cardiff Oncology, Inc.
CRDF
$1.05
-$0.05-4.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 508.00K | 525.00K | 593.00K | 501.00K | 546.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 508.00K | 525.00K | 593.00K | 501.00K | 546.00K |
| Cost of Revenue | 13.27M | 13.27M | 13.27M | 17.91M | 19.35M |
| Gross Profit | -12.76M | -12.75M | -12.68M | -17.41M | -18.81M |
| SG&A Expenses | 16.82M | 16.34M | 14.22M | 14.24M | 13.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.77M | 47.95M | 49.55M | 54.21M | 54.88M |
| Operating Income | -42.27M | -47.43M | -48.96M | -53.71M | -54.33M |
| Income Before Tax | -40.05M | -44.76M | -45.85M | -50.42M | -51.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.05 | -44.76 | -45.85 | -50.42 | -51.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.05M | -44.76M | -45.85M | -50.42M | -51.02M |
| EBIT | -42.27M | -47.43M | -48.96M | -53.71M | -54.33M |
| EBITDA | -41.92M | -47.07M | -48.60M | -53.33M | -53.95M |
| EPS Basic | -0.59 | -0.67 | -0.69 | -0.80 | -0.88 |
| Normalized Basic EPS | -0.37 | -0.42 | -0.43 | -0.50 | -0.55 |
| EPS Diluted | -0.59 | -0.67 | -0.69 | -0.80 | -0.88 |
| Normalized Diluted EPS | -0.37 | -0.42 | -0.43 | -0.50 | -0.55 |
| Average Basic Shares Outstanding | 271.06M | 269.19M | 267.36M | 254.15M | 234.13M |
| Average Diluted Shares Outstanding | 271.06M | 269.19M | 267.36M | 254.15M | 234.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |